1. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2024 году. XVII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2025; 27(3): 8 - 32.

2. Трансплантология: руководство для врачей/Под ред. В.И. Шумакова. - М: Медицинское информационное агентство, 2006. - 544 с. - ISBN 5-89481-453-7.

3. Bussutil, R.W. Transplantation of the Liver: Third Edition/R.W. Bussutil, G. K. Klintmalm. - Philadelphia: Elsevier Saunders, 2015. - 1485 p. - ISBN 9781455702688.

4. Шифф Ю., Мэддрей. Болезни печени по Шиффу: Цирроз печени и его осложнения. Трансплантация печени/Ю.Р. Шифф, М.Ф. Соррел, У.С. Мэддрей; Пер. В.Т. Ивашкин. - М.: ГЭОТАР-Медиа, 2012. - 592 с.

5. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis/R. Loomba, A.K. Rowley, R. Wesley [et al.]//Clinical Gastroenterology and Hepatology. - 2008. - Vol. 6, N 6 - P. 696 - 700.

6. Do Patients with Autoimmune Conditions Have Less Access to Liver Transplantation despite Superior Outcomes?/S. S. Keeling, M.F. McDonald, A. Anand [et al.]//Journal of Personalized Medicine. - 2022. - Vol. 12, N 7. - N 1159.

7. Lucey, M.R. Liver transplantation in patients with alcoholic liver disease/M.R. Lucey//Liver transplantation. - 2011. - Vol. 17, N 7. - P. 751 - 759.

8. Ahmad, J. Hepatology and transplant hepatology - New York: Springer, 2011. - 427 p.

9. Готье С.В. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение регистра Российского трансплантологического общества/С.В. Готье, С.М. Хомяков//Вестник трансплантологии и искусственных органов. - 2020. - Т. XXII, N 2. - С. 8 - 34.

10. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients/G. Fattovich, G. Giustina, F. Degos [et al.]//Gastroenterology. - 1997. - Vol. 112. - P. 463 - 472.

11. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study/K.M. Fleming, G.P. Aithal, T.R. Card, J. West//Liver International. - 2012. - Vol. 32. - P. 79 - 84.

12. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis/A. Zipprich, G. Garcia-Tsao, S. Rogowski [et al.]//Liver International. - 2012. - Vol. 32. - P. 1407 - 1414.

13. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation/P. Martin, A. DiMartini, S. Feng [et al.]//Hepatology. - 2014. - Vol. 59, N 3. - P. 1144 - 1165.

14. A model to examine the validity of the 6-month abstinence criterion for liver transplantation/W.R. Yates, M. Martin, D. LaBrecque [et al.]//Alcoholism: Clinical and Experimental Research. - 1998. - Vol. 22. - P. 513 - 517.

15. Early liver transplantation for severe alcoholic hepatitis/Ph. Mathurin, Ch. Moreno, D. Samuel [et al.]//The New England Journal of Medicine. - 2011. - Vol. 365, N 19. - P. 1790 - 1800.

16. Pavel, M.-C. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions/M.-C. Pavel, J. Fuster//World journal of gastroenterology. - 2018. - Vol. 24, N 32. - P. 3626 - 3636.

17. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis/V. Mazzaferro, E. Regalia, R. Doci [et al.]//The New England Journal of Medicine. - 1996. - Vol. 334, N 11. - P. 693 - 699.

18. Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States/S.S. Patel, A.K. Arrington, Sh. McKenzie [et al.]//International Journal of Hepatology. - 2012. - Vol. 2. - N 253517.

19. Hoti, E. Liver transplantation for primary and metastatic liver cancers/E. Hoti, R. Adam//Transplant International. - 2008. - Vol. 21. - P. 1107 - 1117.

20. Liver transplantation for unresectable colorectal liver metastases: A systematic review/D. Moris, D.I. Tsilimigras, J. Chakedis [et al.]//Journal of Surgical Oncology. - 2017. - Vol. 116, N 3. - P. 288 - 297.

21. Transplantation for colorectal metastases: on the edge of a revolution/A. Andres, G. Oldani, Th. Berney [et al.]//Translational gastroenterology and hepatology. - 2018. - N 3. - P. 74.

22. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases/A. Gorgen, H. Muaddi, W. Zhang [et al.]//Canadian Journal of Gastroenterology and Hepatology. - 2018. - N 9531925.

23. Liver transplantation for nonresectable liver metastases from colorectal cancer/M. Hagness, A. Foss, P.-D. Line [et al.]//Annals of Surgery. - 2013. - Vol. 257. - P. 800 - 806.

24. EASL Clinical Practice Guidelines: Liver transplantation/European Association for the Study of the Liver//Journal of Hepatology. - 2016. - Vol. 64, N 2. - P. 433 - 485.

25. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma/J. Bridgewater, P.R. Galle, Sh.A. Khan [et al.]//Journal of Hepatology. - 2014. - Vol. 60, N 6. - P. 1268 - 1289.

26. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers/S.D. Murad, W.R. Kim, D.M. Harnois [et al.]//Gastroenterology. - 2012. - Vol. 143, N 1. - P. 88 - 98.

27. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024 Dec; 81(6): 1040 - 1086. doi: 10.1016/j.jhep.2024.07.032. Epub 2024 Oct 31. PMID: 39487043.

28. Зубенко С.И., Монахов А.Р., Болдырев М.А., Салимов В.Р., Смолянинова А.Д., Готье С.В. Факторы риска при трансплантации печени от посмертного донора: опыт одного центра. Вестник трансплантологии и искусственных органов. 2022; 24(4): 7 - 14.

29. Инфекционные и септические осложнения трансплантации печени: методические рекомендации/составители: М.С. Новрузбеков, Б.И. Яремин, В.В. Кулабухов, [и др.]. - М.: ГБУЗ "НИИ СП им. Н.В. Склифосовского ДЗМ", 2025. - 72 с.

30. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review/K.I. , R.J. Porte, E. Nadal [et al.]//Transplantation. - 2012. - Vol. 94, N 11. - P. 1145 - 1153.

31. Role of HLA typing and chimerism analysis in post-liver transplantation GVHD in pediatrics: A systematic review/S. Ghandorah, B. Alsawaf, W. Alrefai [et al.]//Pediatric Transplantation. - 2022. - Vol. 26, N 8. - e14381.

32. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis/X. Lan, M.-M. Zhang, C.-L. Pu [et al.]//World Journal of Gastroenterology. - 2010. - Vol. 16, N 27. - P. 3457 - 3464.

33. Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis/H.A. Lee, J.Y. Jung, Y.S. Lee [et al.]//Gut and Liver. - 2021. - Vol. 15, N 4. - P. 599 - 605.

34. Moller, S. Cirrhotic cardiomyopathy/S. Moller, J.H. Henriksen//Journal of Hepatology. - 2010. - Vol. 53, N 1. - P. 179 - 190.

35. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registrybased matched case-control study/J. An, J.H. Shim, S.-O. Kim [et al.]//Circulation. - 2014. - Vol. 130, N 16. - P. 1353 - 1362.

36. Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease/W. Bernal, R. Martin-Mateos, M. Lipcsey [et al.]//Liver transplantation. - 2014. - Vol. 20, N 1. - P. 54 - 62.

37. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study/C. Wray, J.C. Scovotti, J. Tobis [et al.]//American Journal of Transplantation. - 2013. - Vol. 13, N 1. - P. 184 - 191.

38. Umeda, N. Hepatopulmonary syndrome and portopulmonary hypertension/N. Umeda, P.S. Kamath//Hepatology Research. - 2009. - Vol. 39, N 10. - P. 1020 - 1022.

39. Koch, D.G. Hepatopulmonary syndrome/D.G. Koch, M.B. Fallon//Current Opinion in Gastroenterology. - 2014. - Vol. 30. - P. 260 - 264.

40. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation/M.R. Arguedas, G.A. Abrams, M.J. Krowka, M.B. Fallon//Hepatology. - 2003. - Vol. 37, N 1. - P. 192 - 197.

41. Pastor, C.M. Therapy Insight: hepatopulmonary syndrome and orthotopic liver transplantation/C.M. Pastor, E. Schiffer//Nature Reviews Gastroenterology & Hepatology. - 2007. - Vol. 4, N 11. - P. 614 - 621.

42. The impact of treatment of portopulmonary hypertension on survival following liver transplantation/M. Ashfaq, S. Chinnakotla, L. Rogers [et al.]//American Journal of Transplantation. - 2007. - Vol. 7, N 5. - P. 1258 - 1264.

43. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups/K.L. Swanson, R.H. Wiesner, S.L. Nyberg [et al.]//American Journal of Transplantation. - 2008. - Vol. 8, N 11. - P. 2445 - 2453.

44. Hoeper, M.M. Portopulmonary hypertension and hepatopulmonary syndrome/M.M. Hoeper, M.J. Krowka, Ch.P. Strassburg//Lancet. - 2004. - Vol. 363. - P. 1461 - 1468.

45. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol/O.K. Fix, N.M. Bass, T. De Marco, R.B. Merriman//Liver transplantation. - 2007. - Vol. 13, N 6. - P. 875 - 885.

46. Renal failure and cirrhosis: a systematic review of mortality and prognosis/G. Fede, G. D'Amico, V. Arvaniti [et al.]//Journal of Hepatology. - 2012. - Vol. 56, N 4. - P. 810 - 818.

47. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis/F. Wong, M.K. Nadim, J.A. Kellum [et al.]//Gut. - 2011. - Vol. 60. - P. 702 - 709.

48. The evaluation of renal function and disease in patients with cirrhosis/C. Francoz, D. Glotz, R. Moreau, F. Durand//Journal of Hepatology. - 2010. - Vol. 52, N 4. - P. 605 - 613.

49. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK)/J.D. Eason, T.A. Gonwa, C.L. Davis [et al.]//American Journal of Transplantation. - 2008. - Vol. 8, N 11. - P. 2243 - 2251.

50. Objective radiologic assessment of body composition in patients with endstage liver disease: going beyond the BMI/R.J. Cruz Jr, M.A. Dew, L. Myaskovsky [et al.]//Transplantation. - 2013. - Vol. 95, N 4. - P. 617 - 622.

51. Liver transplantation at the extremes of the body mass index/A.A.S Dick, A.L. Spitzer, C.F. Seifert [et al.]//Liver transplantation. - 2009. - Vol. 15, N 8. - P. 968 - 977.

52. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography/F. Durand, S. Buyse, C. Francoz [et al.]//Journal of Hepatology. - 2014. - Vol. 60, N 6. - P. 1151 - 1157.

53. Nair, S. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States/S. Nair, S. Verma, P.J. Thuluvath//Hepatology. - 2002. - Vol. 35, N 1. - P. 105 - 109.

54. Assessing bone status in patients awaiting liver transplantation/C. Wibaux, I. Legroux-Gerot, S. Dharancy [et al.]//Joint Bone Spine. - 2011. - Vol. 78, N 4. - P. 387 - 391.

55. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation/A.A. Vargas 1, J.M.P. Acevedo, I.G. Domingo [et al.]//Transplantation Proceedings. - 2012. - Vol. 44, N 6. - P. 1496 - 1498.

56. The role of donor-specific HLA alloantibodies in liver transplantation/J.G. O'Leary, A.J. Demetris, L.S. Friedman [et al.]//American Journal of Transplantation. - 2014. - Vol. 14, N 4. - P. 779 - 787.

57. Severe sepsis in cirrhosis/Th. Gustot, F. Durand, D. Lebrec, J.-L. Vincent, R. Moreau//Hepatology. - 2009. - Vol. 50, N 6. - P. 2022 - 2033.

58. Management of infections pre- and post-liver transplantation: report of an AISF consensus conference/S. Fagiuoli, A. Colli, R. Bruno [et al.]//Journal of Hepatology. - 2014. - Vol. 60, N 5. - P. 1075 - 1089.

59. Cheruvattath, R. Infections in Patients With End-stage Liver Disease/R. Cheruvattath, V. Balan//Journal of Clinical Gastroenterology. - 2007. - Vol. 41, N 4. - P. 403 - 411.

60. Tandon, P. Bacterial infections, sepsis, and multiorgan failure in cirrhosis/P. Tandon, G. Garcia-Tsao//Seminars in Liver Disease. - 2008. - Vol. 28, N 1. - P. 26 - 42.

61. Caly, W.R. A prospective study of bacterial infections in patients with cirrhosis/W.R. Caly, E. Strauss//Journal of Hepatology. - 1993. - Vol. 18, N 3. - P. 353 - 358.

62. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia/M. Falguera, J. Trujillano, S. Caro [et al.]//Clinical Infectious Diseases. - 2009. - Vol. 49, N 3. - P. 409 - 416.

63. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention/M.S. Niederman, L.A. Mandell, A. Anzueto [et al.]//American Journal of Respiratory and Critical Care Medicine. - 2001. - Vol. 163, N 7. - P. 1730 - 1754.

64. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study/Ph. Lenz, B. Conrad, T. Kucharzik [et al.]//Gastrointestinal Endoscopy. - 2009. - Vol. 70, N 3. - P. 480 - 487.

65. Biliary candida infections in primary sclerosing cholangitis/H. Kulaksiz, G. Rudolph, P. Kloeters-Plachky [et al.]//Journal of Hepatology. - 2006. - Vol. 45, N 5. - P. 711 - 716.

66. Screening of donor and recipient prior to solid organ transplantation/S.A. Fischer, R.K. Avery, AST Infectious Disease Community of Practice//American Journal of Transplantation. - 2009. - Vol. 9, Suppl. 4. - P. S7 - S18.

67. Are HIV-infected patients candidates for liver transplantation?/D. Samuel, R. Weber, P. Stock [et al.]//J Hepatol. - 2008. - Vol. 48, N 5. - P. 697 - 707.

68. Francoz, C. Portal vein thrombosis, cirrhosis, and liver transplantation/C. Francoz, D. Valla, F. Durand//J Hepatol. - 2012. - Vol. 57, N 1. - P. 203 - 212.

69. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma/Y. Asman, A.R. Evenson, E. Even-Sapir, O. Shibolet//Liver transplantation. - 2015. - Vol. 21, N 5. - P. 572 - 580.

70. Model for end-stage liver disease (MELD) and allocation of donor livers/R. Wiesner, E. Edwards, R. Freeman [et al.]//Gastroenterology. - 2003. - Vol. 124, N 1. - P. 91 - 96.

71. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts/M. Malinchoc, P.S. Kamath, F.D. Gordon [et al.]//Hepatology. - 2000. - Vol. 31, N 4. - P. 864 - 871.

72. The survival benefit of liver transplantation/R.M. Merion, D.E. Schaubel, D.M. Dykstra [et al.]//American Journal of Transplantation. - 2005. - Vol. 5, N 2. - P. 307 - 313.

73. MELD and prediction of post-liver transplantation survival/Sh. Habib, B. Berk, Ch.-Ch. H. Chang [et al.]//Liver transplantation. - 2006. - Vol. 12, N 3. - P. 440 - 447.

74. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula/R.B. Freeman Jr, R.G. Gish, A. Harper [et al.]//Liver transplantation. - 2006. - Vol. 12, Suppl. 3. - P. S128 - S136.

75. Goldberg, D.S. Standardizing MELD Exceptions: Current Challenges and Future Directions/D.S. Goldberg, K.M. Olthoff//Current transplantation reports. - 2014. - Vol. 1, N 4. - P. 232 - 237.

76. Song, G.W. Living donor liver transplantation/G.-W. Song, S.-G. Lee//Current Opinion in Organ Transplantation. - 2014. - Vol. 19. - P. 217 - 222.

77. Living donor liver transplantation in children: a single North American center experience over two decades/W. Karnsakul, P. Intihar, R. Konewko [et al.]//Pediatric Transplantation. - 2012. - Vol. 16. - P. 486 - 495.

78. Living donor liver transplantation. Interventional procedure guidance 194. 2011/National Institute for Health and Clinical Excellence. - 2006. URL: http://www.nice.org.uk/guidance/IPG194/Guidance/pdf

79. ABO incompatible pediatric liver transplantation in very small recipients: Birmingham's experience/Th. Gelas, P.J. McKiernan, D.A. Kelly [et al.]//Pediatric Transplantation. - 2011. - Vol. 15. - P. 706 - 711.

80. Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis/J. Wu, S. Ye, X. Xu [et al.]//PLoS One. - 2011. - Vol. 6, N 1. - e16521.

81. Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database/M.D. Kluger, J.V. Guarrera, S.K. Olsen [et al.]//Transplantation. - 2012. - Vol. 94, N 5. - P. 526 - 531.

82. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor/J.M. Kim, Ch.H.D. Kwon, J.-W. Joh [et al.]//Journal of Hepatology. - 2013. - Vol. 59. - P. 1215 - 1222.

83. Protocols and guidelines for children undergoing deceased donor liver transplantation in the UK. Liver Advisory Group/NHSBT. - 2010.

84. Living related donor liver transplantation in children/A.C.A. Tannuri, N.E.M. Gibelli, L.R.S. Ricardi [et al.]//Transplantation Proceedings. - 2011. - Vol. 43, N 1. - P. 161 - 164.

85. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center/M. Ueda, F. Oike, Y. Ogura [et al.]//Liver transplantation. - 2006. - Vol. 12, N 9. - P. 1326 - 1336.

86. Living donor liver transplantation/British Transplantation Society United Kingdom Guidelines. - 2015.

87. Guidelines for Antibody Incompatible Transplantation. Third edition/British Transplantation Society Guidelines. - 2015.

88. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study/J.P. Ong, G. Oehler, Ch. [et al.]//Clinical Drug Investigation. - 2011. - Vol. 31, N 4. - P. 213 - 220.

89. Цирульникова И.Е. Трансплантация печени детям от АВО-несовместимых доноров/Цирульникова Ирина Евгеньевна; ФГБУ "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Минздрава России. - Москва, 2014. - 147 с.

90. Патент N 2582943 Российская Федерация, МПК G01N 33/48(2006.01). Способ десенсибилизации реципиента при АВО-несовместимой трансплантации печени детям раннего возраста: N 2014152866/15: заявл. 25.12.2014 г.: опубл. 27.04.2016 г./Цирульникова О.М., Шевченко О.П., Цирульникова И.Е., Ахаладзе Д.Г., Силина О.В., Джанбеков Т.А., Порунова А.К., Морозова В.В., Готье С.В.; заявитель ФГБУ "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Минздрава России. - 10 с.

91. Патент N 2580640 Российская Федерация, МПК G01N 33/48(2006.01). Способ профилактики гуморального отторжения при АВО-несовместимой трансплантации печени детям раннего возраста: N 2014152864/15: заявл. 25.12.2014 г.: опубл. 10.04.2016 г./Цирульникова О.М., Шевченко О.П., Цирульникова И.Е., Ахаладзе Д.Г., Силина О.В., Джанбеков Т.А., Порунова А.К., Морозова В.В., Готье С.В.; заявитель ФГБУ "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Минздрава России. - 8 с.

92. Иммуносупрессия при трансплантации солидных органов/под ред. С.В. Готье. - М. - Тверь: ООО "Издательство Триада", 2011. - 382 с.

93. Killenberg, P.G. Medical care of the transplant patient. Tonal Pre-, Intra- and Post- Operative Management/P.G. Killenberg, P.-A. Clavien. - India: Blackwell Publishing, 2006. - 597 p.

94. Диагностика острого отторжения аллотрансплантированной печени по схеме БАНФФ-1995. Методические рекомендации/И.М. Ильинский, Н.П. Можейко, Л.В. Шкалова [и др.]. - Москва, 2010. - 24 с.

95. Диагностика острого отторжения по пункционным биоптатам аллотрансплантированной печени/Л.В. Шкалова, Н.П. Можейко, И.М. Ильинский [и др.]//Вестник трансплантологии и искусственных органов. - 2011. - Т. 13, N 3. - С. 15 - 19.

96. International Working Party. Terminology for hepatic allograft rejection//Hepatology. - 1995. - Vol. 22, N 2. - P. 648 - 654.

97. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging/K. Blakolmer, A. Jain, K. Ruppert [et al.]//Transplantation. - 2000. - Vol. 69. - P. 2330 - 2336.

98. Инфекции в трансплантологии/под ред. С.В. Готье. - М. - Тверь: ООО "Издательство Триада", 2010. - 384 с.

99. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis/L.H. Katz, M. Paul, D.G. Guy, R. Tur-Kaspa//Transplant Infectious Disease. - 2010. - Vol. 12, N 4 - P. 292 - 308.

100. Teperman Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation/M.R. Lucey, N. Terrault, L. Ojo [et al.]//Liver Transplantation. - 2013. - Vol. 19, N 1. - P. 3 - 26.

101. The natural history of hepatitis C cirrhosis after liver transplantation/R.J. Firpi, V. Clark, C. Soldevila-Pico [et al.]//Liver transplantation. - 2009. - Vol. 15. - P. 1063 - 1071.

102. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation/J.M. Pascasio, C. Vinaixa, M.T. Ferrer [et al.]//Journal of Hepatology. - 2017. - Vol. 67, N 6. - P. 1168 - 1176.

103. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study/L.S. Belli, M. Berenguer, P.A. Cortesi [et al.]//Journal of Hepatology. - 2016. - Vol. 65, N 3. - P. 524 - 553.

104. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial/M. Manns, D. Samuel, E.J. Gane [et al.]//The Lancet Infectious Diseases. - 2016. - Vol. 16, N 6. - P. 685 - 697.

105. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list/J. Chhatwal, S. Samur, B. Kues [et al.]//Hepatology. - 2017. - Vol. 65, N 3. - P. 777 - 788.

106. The association between hepatitis C infection and survival after orthotopic liver transplantation/L.M. Forman, J.D. Lewis, J.A. Berlin [et al.]//Gastroenterology. - 2002. - Vol. 122, N 4. - P. 889 - 896.

107. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome/N. Selzner, E.L. Renner, M. Selzner [et al.]//Transplantation. - 2009. - Vol. 88, N 10. - P. 1214 - 1221.

108. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection/B.J. Veldt, J.J. Poterucha, K.D.S. Watt//American Journal of Transplantation. - 2008. - Vol. 8, N 11. - P. 2426 - 2433.

109. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study/J.A , M. Navasa, M. [et al.]//Gastroenterology. - 2007. - Vol. 132. - P. 1746 - 1756.

110. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation/M. Berenguer, A. Palau, V. Aguilera [et al.]//American Journal of Transplantation. - 2008. - Vol. 8, N 3. - P. 679 - 687.

111. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation/F.P. Picciotto, G. Tritto, A.G. Lanza [et al.]//Journal of Hepatology. - 2007. - Vol. 46, N 3. - P. 459 - 465.

112. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers/L. Sandmann, P. , A. Wranke [et al.]//European Journal of Gastroenterology & Hepatology. - 2019. - Vol. 31, N 8. - P. 1049 - 1056.

113. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection/Feld JJ, Jacobson IM, Hezode C [et al.]//The New England Journal of Medicine - 2015. - Vol. 373. P. 2599 - 2607.

114. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis/J. Liu, B. Ma, W. Cao [et al.]c//Transplant Infectious Disease. 2019. - Vol. 21, N 2. - e13047.

115. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation/A. Blasco, X. Forns, J.A. [et al.]//Hepatology. - 2006. - Vol. 43., N 3. - P. 492 - 499.

116. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C/U.P. Neumann, Th. Berg, M. Bahra [et al.]//Journal of Hepatology. - 2004. - Vol. 41, N 5. - P. 830 - 836.

117. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence/A.T.W. Song, R. Sobesky, C. Vinaixa [et al.]//World Journal of Gastroenterology. - 2016. - Vol. 22, N 18. - P. 4547 - 4558.

118. Terrault, N.A. Hepatitis C therapy before and after liver transplantation/N.A. Terrault//Liver transplantation. - 2008. - Vol. 14. - P. 58 - 66.

119. Viral hepatitis in liver transplantation/G. Crespo, Z. , M. Navasa, X. Forns//Gastroenterology. - 2012. - Vol. 142, N 6. - P. 1373 - 1383.

120. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis/C.S. Wang, H.H. Ko, E.M. Yoshida [et al.]//American Journal of Transplantation. - 2006. - Vol. 6, N 7. - P. 1586 - 1599.

121. Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin/M. Berenguer//Journal of Hepatology. - 2008. - Vol. 49, N 2. - P. 274 - 287.

122. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation/L. Castells, V. Vargas, H. Allende [et al.]//Journal of Hepatology. - 2005. - Vol. 43, N 1. - P. 53 - 59.

123. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation/T. Zimmermann, W.O. , S. Biesterfeld [et al.]//Transplant International. - 2007. - Vol. 20, N 7. - P. 583 - 590.

124. An interferon-free antiviral regimen for HCV after liver transplantation/P.Y. Kwo, P.S. Mantry, E. Coakley [et al.]//The New England Journal of Medicine. - 2014. - Vol. 371, N 25. - P. 2375 - 2382.

125. Эффективность и безопасность препаратов прямого противовирусного действия у реципиентов печени с рецидивом хронического гепатита C 1 генотипа после трансплантации/О.М. Цирульникова, Д.В. Умрик, И.А. Милосердов [и др.]//Вестник трансплантологии и искусственных органов. - 2018. - Т. XX, N 4. - С. 21 - 27.

126. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial/Manns M, Samuel D, Gane EJ, [et al.]//The Lancet Infectious Diseases. - 2016. - Vol. 16, N 6. - P. 685 - 697.

127. Sofosbuvir/velpatasvir for 12 weeks in genotype 1 - 4 HCV-infected liver transplant recipients/K. Agarwal, L. Castells, B. [et al.]//Journal of Hepatology. - 2018. - Vol. 69, N 3. - P. 603 - 607.

128. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation/M.G. Cardona-Gonzalez, J.D. Goldman, L. Narayan [et al.]//Hepatology Communications. - 2018. - Vol. 2, N 12. - P. 1446 - 1450.

129. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection/N. Reau, P.Y. Kwo, S. Rhee [et al.]//Hepatology. - 2018. - Vol. 68, N 4. - P. 1298 - 1307.

130. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience/Y. Ueda, T. Kobayashi, T. Ikegami [et al.]//Journal of Gastroenterology. - 2019. - Vol. 54, N 7. - P. 660 - 666.

131. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence/F. Poordad, E.R. Schiff, J.M. Vierling [et al.]//Hepatology. - 2016. - Vol. 63, N 5. - P. 1493 - 5105.

132. Tania M Welzel, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Nov; 65(11): 1861 - 1870.

133. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection/European Association for the Study of the Liver//Journal of Hepatology. - 2017. - Vol. 67, N 2. - P. 370 - 398.

134. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal/M.A. Manini, G. Whitehouse, M. Bruce [et al.]//Digestive and Liver Disease. - 2018. - Vol. 50, N 9. - P. 944 - 953.

135. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years/J. Fung, T. Wong, K. Chok [et al.]//Hepatology. - 2017. - Vol. 66, N 4. - P. 1036 - 1044.

136. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety/S.K. Darweesh, A.A. Gad, K. Akroof, Z.A. ElLatif//European Journal of Gastroenterology & Hepatology. - 2019. - Vol. 31, N 5. - P. 607 - 612.

137. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B/J. Fung, S.-Ch. Chan, C. Cheung [et al.]//The American Journal of Gastroenterology. - 2013. - Vol. 108, N 6. - P. 942 - 948.

138. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B/R. Perrillo, M. Buti, F. Durand [et al.]//Liver transplantation. - 2013. - Vol. 19, N 8. - P. 887 - 895.

139. Terrault, N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?/N. Terrault//The American Journal of Gastroenterology. - 2013. - Vol. 108, N 6. - P. 949 - 951.

140. Fox, A.N. The option of HBIG-free prophylaxis against recurrent HBV/A.N. Fox, N.A. Terrault//Journal of Hepatology. - 2012. - Vol. 56, N 5. - P. 1189 - 1197.

141. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis/P. Wang, N.i Tam, H. Wang [et al.]//PLoS One. - 2014. - Vol. 9, N 8. - e104480.

142. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients/I. , C. Loinaz, O. [et al.]//Transplant Infectious Disease. - 2015. - Vol. 17, N 5. - P. 695 - 701.

143. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation/E. Cholongitas, T. Vasiliadis, N. Antoniadis [et a.]//Transplant Infectious Disease. - 2012. - Vol. 14, N 5. - P. 479 - 487.

144. EASL Clinical Practice Guidelines. Management of chronic hepatitis B/European Association For The Study Of The Liver//Journal of Hepatology. - 2009. - Vol. 50, N 2. - P. 227 - 242.

145. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation/F.H. Saner, V.R. Cicinnati, G. Sotiropoulos, S. Beckebaum//Liver International. - 2012. - Vol. 32, N 2. - P. 179 - 188.

146. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience/A. Jain, M. Nalesnik, J. Reyes [et al.]//Annals of Surgery. - 2002. - Vol. 236, N 4. - P. 429 - 436.

147. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial/A. Galioto, A. Semplicini, G. Zanus [et al.]//Liver transplantation. - 2008. - Vol. 14, N 7. - P. 1020 - 1028.

148. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events/I. Laish, M. Braun, E. Mor [et al.]//Liver transplantation. - 2011. - Vol. 17, N 1. - P. 15 - 22.

149. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation/M. Berenguer, M. Prieto, J.M. [et al.]//Hepatology. - 2000. - Vol. 32, N 4. - P. 852 - 858.

150. Fosby, B. Melum Recurrence and rejection in liver transplantation for primary sclerosing cholangitis/B. Fosby, T.H. Karlsen, E. Melum//World Journal of Gastroenterology. - 2012. - Vol. 18, N 1. - P. 1 - 15.

151. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil"/J. Dumortier, E. Giostra, S. Belbouab [et al.]//The American Journal of Gastroenterology. - 2010. - Vol. 105, N 3 - P. 613 - 620.

152. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation/M. Honda, Y. Sugawara, M. Kadohisa [et al.]//Transplantation. - 2018. - Vol. 102, N. 10. - P. 702 - 1709.

153. Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation/J.M. Kim, C.H.D. Kwon, J.-W. Joh [et al.]//Journal of British Surgery. - 2016. - Vol. 103, N. 3. - P. 276 - 283.

154. Lee, E. Ch. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and meta-analysis/E.Ch. Lee, S.H. Kim 2, S.-J. Park//World journal of gastroenterology. - 2017. - Vol. 23, N. 35. - P. 6516 - 6533.

155. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition/R.H. Squires, V. Ng, R. Romero [et al.]//Hepatology. - 2014. - Vol. 60, N. 1. - P. 362 - 398.

156. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin for post-operative sepsis/infection in liver transplantation/E. Jerome, A. Cavazza, K. Menon, M. J. McPhail//Transplant Immunology. - 2022. - Vol. 74. - N 101675.

157. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients/E. G. Playford, A. C. Webster, T. C. Sorrell, J. C. Craig//European Journal of Clinical Microbiology & Infectious Diseases. - 2006. - Vol. 25, N 9. - P. 549 - 561.

158. Neurological complications after orthotopic liver transplantation/P. Amodio, A. Biancardi, S. Montagnese [et al.]//Digestive and Liver Disease. - 2007. - Vol. 39, N 8. - P. 740 - 747.

159. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis/S. K. Asrani, M. D. Leise, C. P. West [et al.]//Hepatology. - 2010. - Vol. 52, N 4. - P. 1360 - 1370.

160. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort/C. Cooper, S. Kanters, M. Klein [et al.]//AIDS. - 2011. - Vol. 25, N 6. - P. 777 - 786.

161. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis/Y.-Sh. Fang, Q. Wu 1, H.-Ch. Zhao [et al.]//Expert Review of Gastroenterology and Hepatology. - 2021. - Vol. 15, N 9. - P. 1065 - 1076.

162. Diagnostic accuracy of cardiac testing for coronary artery disease in potential liver transplant recipients: A systematic review and meta-analysis/N. Tiwari, J. Margapuri, A. Katamreddy [et al.]//International journal of cardiology. Heart and vasculature. - 2021. - Vol. 32. - N 100714.

163. Cerebral Diseases in Liver Transplant Recipients: Systematic Review of Clinical Evidence/P. Dudek, P. Andruszkiewicz, R. Gelo [et al.]//Journal of Clinical Medicine. - 2022. - Vol. 11, N 4. - N 979.

164. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease/T. Nadarevic, V. Giljaca, A. Colli [et al.]//Cochrane Database Syst Rev. - 2021. - Vol. 10, N 10. - CD013362.

165. A single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients/U. Herden, M. Sterneck, B. M. Buchholz [et al.]//Immunity, Inflammation and Disease. - 2021. - Vol. 9, N 4. - P. 1771 - 1780.

166. Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre and post-MELD eras: A systematic review/C. A. Pinto, V. N. Iyer, H. A. H. Albitar [et al.]//Respiratory medicine and research. - 2021. - Vol. 80. - N 100852.

167. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease/A. Colli, T. Nadarevic, D. Miletic [et al.]//The Cochrane database of systematic reviews. - 2021. - Vol. 4, N 4. - CD013346.

168. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)/M. Kathirvel, Sh. Mallick, P. Sethi [et al.]//HPB (Oxford). - 2021. - Vol. 23, N 5. - P. 666 - 674.

169. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study/M. Hashim, A. Alsebaey, A. Ragab [et al.]//Annals of Hepatology. - 2020. - Vol. 19, N 5. - P. 541 - 545.

170. Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy/N. Singh, D. J. Winston, R. R. Razonable [et al.]//The Journal of Infectious Diseases. - 2021. - Vol. 223, N 6. - P. 1073 - 1077.

171. Oliveira, R. A. Perioperative intensive glycemic control for liver transplant recipients to prevent surgical site infection: A systematic review and meta-analysis/R. A. Oliveira, V. de B. Poveda, J. Tanner//Transplant Infectious Disease. - 2020. - Vol. 22, N 6. - e13390.

172. Systematic review on peri-operative lactate measurements to predict outcomes in patients undergoing liver resection/C. Connolly, S. , Th. Niederwieser, F. Primavesi//Journal of Hepato-Biliary-Pancreatic Sciences. - 2020. - Vol. 27, N 7. - P. 359 - 370.

173. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease/C. T. Ferreira, Th. R. da Silveira, S. M. Vieira [et al.]//Journal of Pediatric Gastroenterology and Nutrition. - 2003. - Vol. 37, N 3. - P. 258 - 261.

174. Rhee, Y. Optimizing Vaccination in Adult Patients With Liver Disease and Liver Transplantation/Y. Rhee, B. E. Sha, C. A. Q Santos//Clinical liver disease (Hoboken). - 2020. - Vol. 15, N 2. - P. 63 - 68.

175. Eschenauer, G. A. Antifungal prophylaxis in liver transplant recipients/G. A. Eschenauer, S. W. Lam, P. L. Carver//Liver transplantation. - 2009. - Vol. 15, N 8. - P. 842 - 858.

176. Immunosuppression in pediatric liver transplant recipients: Unique aspects/T. Miloh, A. Barton, J. Wheeler [et al.]//Liver transplantation. - 2017. - Vol. 23, N 2. - P. 244 - 256.

177. Variation in immunosuppression practices among pediatric liver transplant centers-Society of Pediatric Liver Transplantation survey results/V. Slowik, S. M. Lerret, S. J. Lobritto [et al.]//Pediatric Transplantation. 2021 - Vol. 25, N 2. - e13873.

178. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial/R. Volpin, P. Angeli, A. Galioto [et al.]//Liver transplantation. - 2002. - Vol. 8, N 6. - P. 527 - 534.

179. Moini, M. Review on immunosuppression in liver transplantation/M. Moini, M. L. Schilsky, E. M. Tichy//World Journal of Hepatology. - 2015. - Vol. 7, N 10. - P. 1355 - 1368.

180. Ischemic Reperfusion Injury After Liver Transplantation: Is There a Place for Conservative Management?/A. Obed, S. Alsakarneh, M. Abuassi [et al.]//Gastroenterology Research. - 2013. - Vol. 16, N 1. - P. 50 - 55.

181. Готье С.В. Донорство и трансплантация органов в Российской Федерации в 2022 году. XV сообщение регистра Российского трансплантологического общества/С.В. Готье, С.М. Хомяков//Вестник трансплантологии и искусственных органов. - 2023. - Т. 25, N 3. - С. 8 - 30.

182. Immunosuppression in pediatric liver transplant recipients: Unique aspects/T. Miloh, A. Barton, J. Wheeler [et al.]//Liver transplantation. - 2017. - Vol. 23, N 2. - P. 244 - 256.

183. McKiernan, P. Immunosuppression in Pediatric Liver Transplant/P. McKiernan, E. Mitchell//Pediatric Hepatology and Liver Transplantation. - 2019. - Springer, Cham. - P. 555 - 564.

184. Current Practice in Immunosuppression in Pediatric Liver Transplantation/R. Vincenzi, E. A. Fonseca, K. M. O. Roda [et al.]//Current Pharmaceutical Design. - 2020. - Vol. 26, N 28. - P. 3402 - 3405.

185. Hussaini, T. Immunosuppressive pharmacotherapy in liver transplantation/T. Hussaini, S. Erb, E. M. Yoshida//AME Medical Journal. - 2018. - Vol. 3, N 17. - Published: 25 January 2018.

186. Immunosuppressive Drugs in Liver Transplant: An Insight/Ch. Panackel, J. F. Mathew, M. Fawas N, M. Jacob//Journal of Clinical and Experimental Hepatology. 2022. - Vol. 12, N 6. - P. 1557 - 1571.

187. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm/J. M. Kovarik, B. G. Gridelli, S. Martin [et al.]//Pediatric Transplantation. - 2002. - Vol. 6, N 3. - P. 224 - 230.

188. Low-dose steroids do make a difference: Independent risk factors for impaired linear growth after pediatric liver transplantation/Ch. Leiskau, S. Samuel, E.-D. Pfister [et al.]//Pediatric Transplantation. - 2021. - Vol. 25, N 4. - e13989.

189. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus/K. Vondrak, F. Parisi, A. Dhawan [et al.]//Clinical Transplantation. - 2019. - Vol. 33, N 10. - e13698.

190. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients/C. Barau, A. Barrail-Tran, B. Hemerziu [et al.]//Liver transplantation. - 2011. - Vol. 17, N 10. - P. 1152 - 1158.

191. The Pediatric Transplant Protocols and Guide to Management of Transplant Patients/W. Berquist, K. Cox, L. Dyner [et al.]//Stanford Health Care - Pediatric liver transplant program guideline.

192. Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran S, Carrat F, et al. Global real - world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts. J Hepatol 2019; 70(Suppl.)

193. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493 - 1505.

194. H. Omar, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2017; 1 - 11.

195. Te, Helen S.; Agopian, Vatche G.; Demetris, Anthony J.; Kwo, Paul Y.; McGuire, Brendan M.5 et al. AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications. Liver Transplantation 32(3): p 444 - 490, March 2026. | DOI: 10.1097/LVT.0000000000000715

196. Sharma, Pratima; Izzy, Manhal; Ghabril, Marwan S.; Serper, Marina; Clark, Virginia C. et al. AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and post-transplant management of non-graft-related complications. Liver Transplantation (): 10.1097/LVT.0000000000000785, December 17, 2025. | DOI: 10.1097/LVT.0000000000000785

197. European Association for the Study of the Liver et al. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. Journal of Hepatology, Volume 79, Issue 3, 768 - 828

198. Bowlus CL, L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023; 77(2): 659 - 702. doi: 10.1002/hep.32771

199. Ballester MP, Jalan R, Mehta G. Vaccination in liver diseases and liver Transplantation: Recommendations, implications and opportunities in the post-covid era. JHEP Rep. Published online April 26, 2023. doi: 10.1016/j.jhepr.2023.100776

200. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025; 83(2): 453 - 501. doi: 10.1016/j.jhep.2025.03.017

201. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025; 83(2): 502 - 583. doi: 10.1016/j.jhep.2025.03.018

202. Foca M, Demirhan S, Munoz FM, et al. Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients. Open Forum Infect Dis. 2024; 11(7): ofae353. Published 2024 Jul 1. doi: 10.1093/ofid/ofae353

203. Inagaki K, Vander Lugt MT, Riggsbee D, Weinberg JB. Nephrotoxicity of Intravenous Ganciclovir in Pediatric Hematopoietic Cell Transplant Recipients. Pediatr Infect Dis J. 2024; 43(12): 1162 - 1167. doi: 10.1097/INF.0000000000004484

204. Программа СКАТ (Стратегия Контроля Антимикробной Терапии) при оказании стационарной медицинской помощи: Российские практические рекомендации/под ред. С.В. Яковлева, С.В. Сидоренко, Д.Н. Проценко, Н.И. Брико. - 3-е издание, перераб. и доп. - Москва: Издательство "МедКом - Про", 2025. - 345 с.

205. Vivarelli M, Benedetti Cacciaguerra A, Lerut J, et al. Infrarenal versus supraceliac aorto-hepatic arterial revascularisation in adult liver transplantation: multicentre retrospective study. Updates Surg. 2020; 72(3): 659 - 669. doi: 10.1007/s13304-020-00839-x

206. Lorenzin D, Adani GL, Comuzzi C, et al. Comparison of two techniques of arterial anastomosis during adult cadaveric liver transplantation. Transplant Proc. 2007; 39(6): 1879 - 1880. doi: 10.1016/j.transproceed.2007.05.008

207. Bhatti ABH, Khan S, Farooq MH, Ishtiaq W, Khan NY. Liver transplantation with interposition saphenous vein conduits for arterial reconstruction: Impact of morbidity and arterial ischemia time. Surgery. 2023; 174(5): 1263 - 1269. doi: 10.1016/j.surg.2023.08.012

208. Chan T, DeGirolamo K, Chartier-Plante S, Buczkowski AK. Comparison of three caval reconstruction techniques in orthotopic liver transplantation: A retrospective review. Am J Surg. 2017; 213(5): 943 - 949. doi: 10.1016/j.amjsurg.2017.03.045

209. Khajeh E, Ramouz A, Aminizadeh E, et al. Comparison of the modified piggyback with standard piggyback and conventional orthotopic liver transplantation techniques: a network meta-analysis. HPB (Oxford). 2023; 25(7): 732 - 746. doi: 10.1016/j.hpb.2023.02.017

210. Shamsaeefar A, Shafiee M, Nikeghbalian S, et al. Biliary reconstruction in liver transplant patients with primary sclerosing cholangitis, duct-to-duct or Roux-en-Y?. Clin Transplant. 2017; 31(6): 10.1111/ctr.12964. doi: 10.1111/ctr.12964

211. Dancs PT, Pohlmann MC, Bednarsch J, Rashidi-Alavijeh J, Schmitz SM, Kroh A, Ulmer F, Vondran FWR, Neumann UP, Hoyer DP, et al. Biliary Reconstruction in Liver Transplantation with Primary Sclerosing Cholangitis: Roux-en-Y Hepaticojejunostomy or Duct-to-Duct Anastomosis? Journal of Clinical Medicine. 2025; 14(23): 8518.

212. Rajendran V, Joy D, Sudheer Mohammed, Chandran B, Jacob M. Management of Preoperative Recipient Portal Vein Thrombosis in Living-donor Liver Transplantation. J Clin Exp Hepatol. 2025; 15(2): 102445. doi: 10.1016/j.jceh.2024.102445

213. Polat KY, Yazar , A, et al. Management of Non-neoplastic Portal Vein Thrombosis in Adult Living Donor Liver Transplantation. Transplant Proc. 2025; 57(9): 1804 - 1807. doi: 10.1016/j.transproceed.2025.09.001

214. Sancio JB, Ponte RV, Beduschi T, Soma D. Portal Vein Thrombosis, Management and Approaches in Liver Transplantation: A Narrative Review. J Clin Med. 2025; 14(17): 6100. Published 2025 Aug 28. doi: 10.3390/jcm14176100

215. Safarova Y, Meshcheriakov S, Monakhov A, et al. 301.4: Vacuum-assisted laparostomy for delayed abdominal closure in pediatric liver transplantation: A case series. Transplantation. 2024; 108(9S). doi: 10.1097/01.tp.0001065176.38409.a8

216. Molino JA, Hidalgo E, Quintero J, et al. Delayed sequential abdominal wall closure in pediatric liver transplantation to overcome "large for size" scenarios. Pediatr Transplant. 2022; 26(1): e14132. doi: 10.1111/petr.14132

217. Sakamoto S. Armamentarium to overcome "large-for-size" scenarios in pediatric liver transplantation: Graft reduction or delayed abdominal wall closure? Pediatr Transplant. 2022; 26(1): e14177. doi: 10.1111/petr.14177

218. Yoshizumi T, Mori M. Portal flow modulation in living donor liver transplantation: review with a focus on splenectomy. Surg Today. 2020; 50(1): 21 - 29. doi: 10.1007/s00595-019-01881-y

219. Del Prete L, Quintini C, Diago Uso T. The small-for-size syndrome in living donor liver transplantation: current management. Updates Surg. 2025; 77(6): 1797 - 1806. doi: 10.1007/s13304-024-01964-7

220. Mazzaferro V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis//New England Journal of Medicine. - 1996. - Т. 334. - N. 11. - С. 693 - 700.

221. Lingiah V, Niazi M, Olivo R, Paterno F, Guarrera J, Pyrsopoulos N. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol. 2020; 8(1): 69 - 75.

222. Seth I, Siu A, Hewitt L, Budak U, Farah B, Jaber M. Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review. J Gastrointest Cancer. 2024 Mar; 55(1): 318 - 331.

223. Reschen M. E., O'Callaghan C. A. Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus//Transplant Research and Risk Management. - 2014. - С. 55 - 72.